首页 > 最新文献

Journal of Thrombosis and Haemostasis最新文献

英文 中文
Early thrombus formation is required for eccentric and heterogeneous neointimal hyperplasia under disturbed flow 在血流紊乱的情况下,偏心和异源性新内膜增生需要早期血栓形成。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.jtha.2024.07.028
Hualong Bai , Zhuo Li , Weichang Zhang , Carly Thaxton , Yuichi Ohashi , Luis Gonzalez , Masaki Kano , Bogdan Yatsula , John Hwa , Alan Dardik

Background

Anticoagulation and antiplatelet therapy effectively inhibit neointimal hyperplasia (NIH) in both arterial and venous systems but not in arteriovenous fistulae (AVF). The main site of AVF failure is the juxta-anastomotic area that is characterized by disturbed flow compared with laminar flow in the arterial inflow and the venous outflow.

Objectives

We hypothesized that early thrombus formation is required for eccentric and heterogeneous NIH in the presence of disturbed flow.

Methods

Needle puncture and sutured AVF were created in C57BL/6 mice, in PF4-Cre × mT/mG reporter mice, and in Wistar rats. Human AVF samples were second-stage basilic vein transpositions. The tissues were examined by histology, immunofluorescence, immunohistochemistry, and en face staining.

Results

In the presence of disturbed flow, both mouse and human AVF showed eccentric and heterogeneous NIH. Maladapted vein wall was characterized by eccentric and heterogeneous neointima that was composed of a different abundance of thrombus and smooth muscle cells. PF4-cre × mT/mG reporter mice AVF showed that green fluorescent protein-labeled platelets deposit on the wall directly facing the fistula exit with endothelial cell loss and continue to accumulate in the presence of disturbed flow. Neither disturbed flow with limited endothelial cell loss nor nondisturbed flow induced heterogeneous neointima in different animal models.

Conclusion

Early thrombus contributes to late heterogeneous NIH in the presence of disturbed flow. Disturbed flow, large area of endothelial cell loss, and thrombus formation are critical to form eccentric and heterogeneous NIH. Categorization of adapted or maladapted walls may be helpful for therapy targeting heterogeneous NIH.
背景:抗凝和抗血小板疗法能有效抑制动脉和静脉系统的新内膜增生(NIH),但不能抑制动静脉瘘(AVF)。动静脉瘘失败的主要部位是吻合口附近区域,与动脉流入和静脉流出的层流相比,该区域的特点是血流紊乱。我们假设,在血流紊乱的情况下,偏心和异源性 NIH 需要早期血栓形成:方法:在 C57BL/6 小鼠、PF4-cre × mT/mG 报告小鼠和 Wistar 大鼠身上建立针刺和缝合的动静脉瘘。转位收获人类动静脉瘘样本。通过组织学、免疫荧光、免疫组织化学和表面染色对组织进行检查:结果:在血流紊乱的情况下,小鼠和人类的动静脉瘘都表现出偏心和异质的 NIH。适应不良的静脉壁表现为偏心和异质的新内膜,由不同数量的血栓和平滑肌细胞(SMC)组成。PF4-cre × mT/mG 报告小鼠 AVF 显示,GFP 标记的血小板沉积在直接面向瘘管出口的静脉壁上,内皮细胞脱落,并在血流紊乱的情况下继续聚集。在不同的动物模型中,内皮细胞损失有限的干扰血流和非干扰血流都不会诱发异源性新生内膜:结论:在血流紊乱的情况下,早期血栓会导致晚期异源性新生内膜。干扰血流、大面积内皮细胞缺失和血栓形成是形成偏心和异源性 NIH 的关键。对适应或不适应的血管壁进行分类可能有助于针对异源性 NIH 的治疗。
{"title":"Early thrombus formation is required for eccentric and heterogeneous neointimal hyperplasia under disturbed flow","authors":"Hualong Bai ,&nbsp;Zhuo Li ,&nbsp;Weichang Zhang ,&nbsp;Carly Thaxton ,&nbsp;Yuichi Ohashi ,&nbsp;Luis Gonzalez ,&nbsp;Masaki Kano ,&nbsp;Bogdan Yatsula ,&nbsp;John Hwa ,&nbsp;Alan Dardik","doi":"10.1016/j.jtha.2024.07.028","DOIUrl":"10.1016/j.jtha.2024.07.028","url":null,"abstract":"<div><h3>Background</h3><div>Anticoagulation and antiplatelet therapy effectively inhibit neointimal hyperplasia (NIH) in both arterial and venous systems but not in arteriovenous fistulae (AVF). The main site of AVF failure is the juxta-anastomotic area that is characterized by disturbed flow compared with laminar flow in the arterial inflow and the venous outflow.</div></div><div><h3>Objectives</h3><div>We hypothesized that early thrombus formation is required for eccentric and heterogeneous NIH in the presence of disturbed flow.</div></div><div><h3>Methods</h3><div>Needle puncture and sutured AVF were created in C57BL/6 mice, in PF4-Cre × mT/mG reporter mice, and in Wistar rats. Human AVF samples were second-stage basilic vein transpositions. The tissues were examined by histology, immunofluorescence, immunohistochemistry, and en face staining.</div></div><div><h3>Results</h3><div>In the presence of disturbed flow, both mouse and human AVF showed eccentric and heterogeneous NIH. Maladapted vein wall was characterized by eccentric and heterogeneous neointima that was composed of a different abundance of thrombus and smooth muscle cells. PF4-cre × mT/mG reporter mice AVF showed that green fluorescent protein-labeled platelets deposit on the wall directly facing the fistula exit with endothelial cell loss and continue to accumulate in the presence of disturbed flow. Neither disturbed flow with limited endothelial cell loss nor nondisturbed flow induced heterogeneous neointima in different animal models.</div></div><div><h3>Conclusion</h3><div>Early thrombus contributes to late heterogeneous NIH in the presence of disturbed flow. Disturbed flow, large area of endothelial cell loss, and thrombus formation are critical to form eccentric and heterogeneous NIH. Categorization of adapted or maladapted walls may be helpful for therapy targeting heterogeneous NIH.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Pages 3614-3628"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk 人类和狗体内未检测到 FVIII 内含子-22 倒位,这对有关抑制剂风险的假设提出了挑战。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.jtha.2024.08.007
Pooja Vir , Devi Gunasekera , Batsukh Dorjbal , Dennis McDaniel , Atul Agrawal , Elizabeth P. Merricks , Margaret V. Ragni , Cindy A. Leissinger , Allen I. Stering , Kenneth Lieuw , Timothy C. Nichols , Kathleen P. Pratt

Background

Almost half of severe hemophilia A (HA) cases are caused by an intron 22 inversion (Int22Inv) mutation, which truncates the 26-exon F8 messenger RNA (mRNA) after exon 22. Another F8 transcript, F8B, is initiated from within F8-intron-22. F8B mRNA consists of a short exon spliced to exons 23 to 26 and is expressed in multiple human cell types. It has been hypothesized that Int22Inv patients have self-tolerance to partial factor (F)VIII proteins expressed from these 2 transcripts. FVIII is expressed in endothelial cells, primarily in the liver and lungs. Several studies have reported FVIII expression in other cell types, although this has been controversial.

Objectives

To determine if partial FVIII proteins are expressed from intron 22–inverted and/or F8B mRNA and if FVIII is expressed in nonendothelial cells.

Methods

A panel of FVIII-specific antibodies was validated and employed to label FVIII in cells and tissues and for immunoprecipitation followed by western blots and mass spectrometry proteomics analysis.

Results

Immunofluorescent staining localized FVIII to endothelial cells in liver sections from non-HA but not HA-Int22Inv dogs. Neither FVIII nor FVIIIB was detected in human peripheral blood mononuclear cells, B cell or T cell lines, or cell lines expanded from peripheral blood mononuclear cells, whereas FVIII antigen and activity were readily detected in primary nonhemophilic liver sinusoidal endothelial cells.

Conclusion

If FVIII is expressed in nonendothelial cells or if partial FVIII proteins are expressed in HA-Int22Inv, the concentrations are below the detection limits of these sensitive assays. Our results argue against promotion of immune tolerance through expression of partial FVIII proteins in Int-22Inv patients.
背景:近一半的严重 A 型血友病(HA)病例是由内含子-22 倒位突变(Int22Inv)引起的,这种突变会在外显子 22 之后截断 26 外显子 F8 mRNA。另一个 F8 转录本 F8B 从 F8 内含子-22 开始。F8B mRNA 由一个短外显子剪接成 23-26 号外显子,在多种人类细胞类型中表达。据推测,Int22Inv 患者对这两种转录本表达的部分 FVIII 蛋白具有自身耐受性。FVIII 主要在肝脏和肺部的内皮细胞中表达。一些研究报告称 FVIII 在其他细胞类型中也有表达,但这一点一直存在争议:目的:确定部分 FVIII 蛋白是否由内含子 22 倒置和/或 F8B mRNA 表达,以及 FVIII 是否在非内皮细胞中表达:方法: 验证并使用一组FVIII特异性抗体标记细胞和组织中的FVIII,并进行免疫沉淀,然后进行Western印迹和质谱-蛋白质组学分析:结果:免疫荧光(IF)染色将 FVIII 定位于非 HA 而非 HA-Int22Inv 狗肝脏切片的内皮细胞。在人类 PBMCs、B 细胞系或 T 细胞系或由 PBMCs 扩增的细胞系中均未检测到 FVIII 或 FVIIIB,而在原代非血友病肝窦内皮细胞中很容易检测到 FVIII 抗原和活性:结论:如果 FVIII 在非内皮细胞中表达,或部分 FVIII 蛋白在 HA-Int22Inv 中表达,则其浓度低于这些灵敏检测方法的检测限。我们的结果表明,Int-22Inv 患者体内部分 FVIII 蛋白的表达不会促进免疫耐受。
{"title":"Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk","authors":"Pooja Vir ,&nbsp;Devi Gunasekera ,&nbsp;Batsukh Dorjbal ,&nbsp;Dennis McDaniel ,&nbsp;Atul Agrawal ,&nbsp;Elizabeth P. Merricks ,&nbsp;Margaret V. Ragni ,&nbsp;Cindy A. Leissinger ,&nbsp;Allen I. Stering ,&nbsp;Kenneth Lieuw ,&nbsp;Timothy C. Nichols ,&nbsp;Kathleen P. Pratt","doi":"10.1016/j.jtha.2024.08.007","DOIUrl":"10.1016/j.jtha.2024.08.007","url":null,"abstract":"<div><h3>Background</h3><div>Almost half of severe hemophilia A (HA) cases are caused by an intron 22 inversion (Int22Inv) mutation, which truncates the 26-exon <em>F8</em> messenger RNA (mRNA) after exon 22. Another <em>F8</em> transcript, <em>F8</em><sub><em>B</em></sub>, is initiated from within <em>F8</em>-intron-22. <em>F8</em><sub><em>B</em></sub> mRNA consists of a short exon spliced to exons 23 to 26 and is expressed in multiple human cell types. It has been hypothesized that Int22Inv patients have self-tolerance to partial factor (F)VIII proteins expressed from these 2 transcripts. FVIII is expressed in endothelial cells, primarily in the liver and lungs. Several studies have reported FVIII expression in other cell types, although this has been controversial.</div></div><div><h3>Objectives</h3><div>To determine if partial FVIII proteins are expressed from intron 22–inverted and/or <em>F8</em><sub><em>B</em></sub> mRNA and if FVIII is expressed in nonendothelial cells.</div></div><div><h3>Methods</h3><div>A panel of FVIII-specific antibodies was validated and employed to label FVIII in cells and tissues and for immunoprecipitation followed by western blots and mass spectrometry proteomics analysis.</div></div><div><h3>Results</h3><div>Immunofluorescent staining localized FVIII to endothelial cells in liver sections from non-HA but not HA-Int22Inv dogs. Neither FVIII nor FVIII<sub>B</sub> was detected in human peripheral blood mononuclear cells, B cell or T cell lines, or cell lines expanded from peripheral blood mononuclear cells, whereas FVIII antigen and activity were readily detected in primary nonhemophilic liver sinusoidal endothelial cells.</div></div><div><h3>Conclusion</h3><div>If FVIII is expressed in nonendothelial cells or if partial FVIII proteins are expressed in HA-Int22Inv, the concentrations are below the detection limits of these sensitive assays. Our results argue against promotion of immune tolerance through expression of partial FVIII proteins in Int-22Inv patients.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Pages 3415-3430"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical validation and application of targeted long-range polymerase chain reaction and long-read sequencing–based analysis for hemophilia: experience from a hemophilia treatment center in China 基于长程定量 PCR 和长序列测序的血友病靶向分析的临床验证和应用:来自中国一家血友病治疗中心的经验。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.jtha.2024.08.013
Meizhen Shi , Yunting Ma , Xianwei Peng , Xu Zhou , Zifeng Cheng , Bobo Xie , Xianda Wei , Chunrong Gui , Aiping Mao , Wenting Lin , Jiefeng Luo , Yinghui Lai , Baoheng Gui

Background

Targeted long-read sequencing (LRS) is expected to comprehensively analyze diverse complex variants in hemophilia A (HA) and hemophilia B (HB) caused by the F8 and F9 genes, respectively. However, its clinical applicability still requires extensive validation.

Objectives

To evaluate the clinical applicability of targeted LRS-based analysis compared with routine polymerase chain reaction (PCR)–based methods.

Methods

Gene variants of retrieved subjects were retrospectively and prospectively analyzed. Whole-genome sequencing was performed to further analyze undiagnosed cases. Breakpoints of novel genomic rearrangements were mapped and validated using long-distance PCR and long-range PCR combined with sequencing.

Results

In total, 122 subjects were retrieved. In retrospective analysis of the 90 HA cases, HA-LRS assay showed consistent results in 84 cases compared with routine methods and characterized 6 large deletions with their exact breakpoints confirmed by further validation in 6 cases (routine methods only presented failure in amplifying the involved exons). In prospective analysis of the 21 HA subjects, 20 variants of F8 were identified in 20 cases. For the remaining HA patient, no duplication/deletion or single-nucleotide variant (SNV)/insertion and deletion (InDel) was found, but a potential recombination involving exons 14 and 21 of F8 was observed by LRS. Whole-genome sequencing analysis and further verification defined a 30 478 base pairs (bp) tandem repeat involving exons 14 to 21 of F8. Among the 11 HB patients, HB-LRS analysis detected 11 SNVs/InDels in F9, consistent with routine methods.

Conclusion

Targeted LRS-based analysis was efficient and comprehensive in identifying SNVs/InDels and genomic rearrangements of hemophilia genes, especially when we first expanded the panel to include F9. However, further investigation for complex gross rearrangement is still essential.
背景靶向长读测序(LRS)有望全面分析分别由 F8 和 F9 基因引起的血友病 A(HA)和血友病 B(HB)的各种复杂变异。方法对检索对象的基因变异进行回顾性和前瞻性分析。为进一步分析未确诊病例,还进行了全基因组测序(WGS)。利用长程 PCR 和长程 PCR 结合测序技术绘制并验证了新型基因组重排的断点。在对 90 例 HA 病例的回顾性分析中,与常规方法相比,HA-LRS 检测法在 84 例病例中显示出一致的结果,并在 6 例病例中通过进一步验证确认了 6 个大缺失的特征及其确切断点(常规方法仅在扩增涉及的外显子时出现失败)。在对 21 名 HA 受试者的前瞻性分析中,在 20 个病例中发现了 20 个 F8 变异。其余一名 HA 患者没有发现重复/缺失或 SNV/InDel,但通过 LRS 观察到了涉及 F8 第 14 和 21 号外显子的潜在重组。WGS 分析和进一步验证确定了涉及 F8 第 14-21 号外显子的 30,478bp 串联重复。结论基于 LRS 的靶向分析能高效、全面地鉴定血友病基因的 SNVs/InDels 和基因组重排,尤其是我们首次扩大了包括 F9 基因在内的面板。然而,进一步研究复杂的总重排仍是必要的。
{"title":"Clinical validation and application of targeted long-range polymerase chain reaction and long-read sequencing–based analysis for hemophilia: experience from a hemophilia treatment center in China","authors":"Meizhen Shi ,&nbsp;Yunting Ma ,&nbsp;Xianwei Peng ,&nbsp;Xu Zhou ,&nbsp;Zifeng Cheng ,&nbsp;Bobo Xie ,&nbsp;Xianda Wei ,&nbsp;Chunrong Gui ,&nbsp;Aiping Mao ,&nbsp;Wenting Lin ,&nbsp;Jiefeng Luo ,&nbsp;Yinghui Lai ,&nbsp;Baoheng Gui","doi":"10.1016/j.jtha.2024.08.013","DOIUrl":"10.1016/j.jtha.2024.08.013","url":null,"abstract":"<div><h3>Background</h3><div>Targeted long-read sequencing (LRS) is expected to comprehensively analyze diverse complex variants in hemophilia A (HA) and hemophilia B (HB) caused by the <em>F8</em> and <em>F9</em> genes, respectively. However, its clinical applicability still requires extensive validation.</div></div><div><h3>Objectives</h3><div>To evaluate the clinical applicability of targeted LRS-based analysis compared with routine polymerase chain reaction (PCR)–based methods.</div></div><div><h3>Methods</h3><div>Gene variants of retrieved subjects were retrospectively and prospectively analyzed. Whole-genome sequencing was performed to further analyze undiagnosed cases. Breakpoints of novel genomic rearrangements were mapped and validated using long-distance PCR and long-range PCR combined with sequencing.</div></div><div><h3>Results</h3><div>In total, 122 subjects were retrieved. In retrospective analysis of the 90 HA cases, HA-LRS assay showed consistent results in 84 cases compared with routine methods and characterized 6 large deletions with their exact breakpoints confirmed by further validation in 6 cases (routine methods only presented failure in amplifying the involved exons). In prospective analysis of the 21 HA subjects, 20 variants of <em>F8</em> were identified in 20 cases. For the remaining HA patient, no duplication/deletion or single-nucleotide variant (SNV)/insertion and deletion (InDel) was found, but a potential recombination involving exons 14 and 21 of <em>F8</em> was observed by LRS. Whole-genome sequencing analysis and further verification defined a 30 478 base pairs (bp) tandem repeat involving exons 14 to 21 of <em>F8</em>. Among the 11 HB patients, HB-LRS analysis detected 11 SNVs/InDels in <em>F9</em>, consistent with routine methods.</div></div><div><h3>Conclusion</h3><div>Targeted LRS-based analysis was efficient and comprehensive in identifying SNVs/InDels and genomic rearrangements of hemophilia genes, especially when we first expanded the panel to include <em>F9</em>. However, further investigation for complex gross rearrangement is still essential.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Pages 3431-3447"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142182689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The eccentric nature of the neointima
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.jtha.2024.08.005
Filipe F. Stoyell-Conti , Laisel Martinez , Roberto I. Vazquez-Padron
{"title":"The eccentric nature of the neointima","authors":"Filipe F. Stoyell-Conti ,&nbsp;Laisel Martinez ,&nbsp;Roberto I. Vazquez-Padron","doi":"10.1016/j.jtha.2024.08.005","DOIUrl":"10.1016/j.jtha.2024.08.005","url":null,"abstract":"","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Pages 3397-3399"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shifting focus from venous to arterial thromboembolism in patients with cancer
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.jtha.2024.09.020
Anniek Strijdhorst , Nick van Es
{"title":"Shifting focus from venous to arterial thromboembolism in patients with cancer","authors":"Anniek Strijdhorst ,&nbsp;Nick van Es","doi":"10.1016/j.jtha.2024.09.020","DOIUrl":"10.1016/j.jtha.2024.09.020","url":null,"abstract":"","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Pages 3403-3405"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RUNX1 isoforms regulate RUNX1 and target genes differentially in platelets-megakaryocytes: association with clinical cardiovascular events RUNX1 异构体对血小板-巨核细胞中的 RUNX1 和靶基因有不同的调控作用:与临床心血管事件的关系
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.jtha.2024.07.032
Liying Guan , Deepak Voora , Rachel Myers , Fabiola Del Carpio-Cano , A. Koneti Rao

Background

Hematopoietic transcription factor RUNX1 is expressed from proximal P2 and distal P1 promoters to yield isoforms RUNX1 B and C, respectively. The roles of these isoforms in RUNX1 autoregulation and downstream gene regulation in megakaryocytes and platelets are unknown.

Objectives

To understand the regulation of RUNX1 and its target genes by RUNX1 isoforms.

Methods

We performed studies on RUNX1 isoforms in megakaryocytic human erythroleukemia (HEL) cells and HeLa cells (lack endogenous RUNX1), in platelets from 85 healthy volunteers administered aspirin or ticagrelor, and on the association of RUNX1 target genes with acute events in 587 patients with cardiovascular disease (CVD).

Results

In chromatin immunoprecipitation and luciferase promoter assays, RUNX1 isoforms B and C bound and regulated P1 and P2 promoters. In HeLa cells, RUNX1B decreased and RUNX1C increased P1 and P2 activities, respectively. In HEL cells, RUNX1B overexpression decreased RUNX1C and RUNX1A expression; RUNX1C increased RUNX1B and RUNX1A. RUNX1B and RUNX1C regulated target genes (MYL9, F13A1, PCTP, PDE5A, and others) differentially in HEL cells. In platelets, RUNX1B transcripts (by RNA sequencing) correlated negatively with RUNX1C and RUNX1A; RUNX1C correlated positively with RUNX1A. RUNX1B correlated positively with F13A1, PCTP, PDE5A, RAB1B, and others, and negatively with MYL9. In our previous studies, RUNX1C transcripts in whole blood were protective against acute events in CVD patients. We found that higher expression of RUNX1 targets F13A1 and RAB31 associated with acute events.

Conclusion

RUNX1 isoforms B and C autoregulate RUNX1 and regulate downstream genes in a differential manner, and this is associated with acute events in CVD.
背景:造血转录因子 RUNX1 由近端 P2 和远端 P1 启动子表达,分别产生异构体 RUNX1 B 和 C。这些异构体在巨核细胞和血小板中的 RUNX1 自调节和下游基因调节中的作用尚不清楚:目的:了解 RUNX1 及其靶基因受 RUNX1 同工酶调控的情况:我们对巨核细胞HEL细胞和HeLa细胞(缺乏内源性RUNX1)中的RUNX1同工酶、85名服用阿司匹林或替卡格雷的健康志愿者的血小板中的RUNX1同工酶以及587名心血管疾病(CVD)患者的RUNX1靶基因与急性事件的相关性进行了研究:结果:在染色质免疫沉淀和荧光素酶启动子试验中,RUNX1同工酶B和C与P1和P2启动子结合并对其进行调控。在 HeLa 细胞中,RUNX1B 分别降低了 P1 和 P2 的活性,而 RUNX1C 则提高了 P1 和 P2 的活性。在 HEL 细胞中,RUNX1B 过表达会降低 RUNX1C 和 RUNX1A 的表达;RUNX1C 会增加 RUNX1B 和 RUNX1A 的表达。在 HEL 细胞中,RUNX1B 和 RUNX1C 对靶基因(MYL9、F13A1、PCTP、PDE5A 等)的调控存在差异。在血小板中,RUNX1B 转录物(通过 RNAseq)与 RUNX1C 和 RUNX1A 呈负相关;RUNX1C 与 RUNX1A 呈正相关。RUNX1B 与 F13A1、PCTP、PDE5A、RAB1B 等呈正相关,与 MYL9 呈负相关。在我们之前的研究中,全血中的 RUNX1C 转录物对心血管疾病患者的急性事件具有保护作用。我们发现,RUNX1靶标F13A1和RAB31的高表达与急性事件有关:结论:RUNX1同工酶B和C以不同的方式自动调节RUNX1并调控下游基因,这与心血管疾病的急性事件有关。
{"title":"RUNX1 isoforms regulate RUNX1 and target genes differentially in platelets-megakaryocytes: association with clinical cardiovascular events","authors":"Liying Guan ,&nbsp;Deepak Voora ,&nbsp;Rachel Myers ,&nbsp;Fabiola Del Carpio-Cano ,&nbsp;A. Koneti Rao","doi":"10.1016/j.jtha.2024.07.032","DOIUrl":"10.1016/j.jtha.2024.07.032","url":null,"abstract":"<div><h3>Background</h3><div>Hematopoietic transcription factor RUNX1 is expressed from proximal P2 and distal P1 promoters to yield isoforms RUNX1 B and C, respectively. The roles of these isoforms in RUNX1 autoregulation and downstream gene regulation in megakaryocytes and platelets are unknown.</div></div><div><h3>Objectives</h3><div>To understand the regulation of <em>RUNX1</em> and its target genes by RUNX1 isoforms.</div></div><div><h3>Methods</h3><div>We performed studies on RUNX1 isoforms in megakaryocytic human erythroleukemia (HEL) cells and HeLa cells (lack endogenous RUNX1), in platelets from 85 healthy volunteers administered aspirin or ticagrelor, and on the association of RUNX1 target genes with acute events in 587 patients with cardiovascular disease (CVD).</div></div><div><h3>Results</h3><div>In chromatin immunoprecipitation and luciferase promoter assays, RUNX1 isoforms B and C bound and regulated P1 and P2 promoters. In HeLa cells, RUNX1B decreased and RUNX1C increased P1 and P2 activities, respectively. In HEL cells, RUNX1B overexpression decreased RUNX1C and RUNX1A expression; RUNX1C increased RUNX1B and RUNX1A. RUNX1B and RUNX1C regulated target genes (<em>MYL9</em>, <em>F13A1</em>, <em>PCTP</em>, <em>PDE5A</em>, and others) differentially in HEL cells. In platelets, <em>RUNX1B</em> transcripts (by RNA sequencing) correlated negatively with <em>RUNX1C</em> and <em>RUNX1A</em>; <em>RUNX1C</em> correlated positively with <em>RUNX1A</em>. <em>RUNX1B</em> correlated positively with <em>F13A1</em>, <em>PCTP</em>, <em>PDE5A</em>, <em>RAB1B</em>, and others, and negatively with <em>MYL9</em>. In our previous studies, <em>RUNX1C</em> transcripts in whole blood were protective against acute events in CVD patients. We found that higher expression of RUNX1 targets <em>F13A1</em> and <em>RAB31</em> associated with acute events.</div></div><div><h3>Conclusion</h3><div>RUNX1 isoforms B and C autoregulate <em>RUNX1</em> and regulate downstream genes in a differential manner, and this is associated with acute events in CVD.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Pages 3581-3598"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients 用 Xa 因子抑制剂治疗严重肥胖患者的心房颤动和静脉血栓栓塞。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.jtha.2024.08.009
Paul Dobry , Stephanie B. Edwin , Brian Haymart , Geoffrey D. Barnes , Scott Kaatz , Mona A. Ali , Christopher Giuliano

Background

A paucity of data exists to support the use of factor (F)Xa inhibitors in severely obese patients with a weight of ≥150 kg or body mass index (BMI) of ≥50 kg/m2.

Objectives

The purpose of this study was to evaluate whether FXa inhibitors are as safe and effective as warfarin for the treatment of atrial fibrillation (AF) and/or venous thromboembolism (VTE) in individuals with a BMI of ≥50 kg/m2 and/or weight of ≥150 kg.

Methods

This was a multicenter retrospective cohort study of severely obese adult patients with AF and/or VTE treated with a FXa inhibitor or warfarin. The primary effectiveness outcome was composite odds of stroke, systemic embolism, or VTE; the primary safety outcome was odds of major bleeding. Secondary outcomes included incidence of stroke or systemic embolism, VTE, major bleeding, clinically relevant nonmajor bleeding, all-cause mortality, change in anticoagulation, and total number of hospital encounters. Outcomes were assessed for 12 months following initiation of study drug.

Results

A total of 1736 patients were included. The mean weight and BMI of the overall cohort were 164.4 kg and 54.6 kg/m2, respectively. There was no difference in odds of stroke, systemic embolism or VTE (odds ratio, 1.005; 95% CI, 0.6-1.68), or major bleeding (odds ratio, 0.9; 95% CI, 0.47-1.7) between groups.

Conclusion

These data suggest that apixaban and rivaroxaban are safe and effective alternatives to warfarin for the treatment of AF and/or VTE in individuals with a BMI of ≥50 kg/m2 and/or weight of ≥150 kg.
背景:在体重≥150公斤或体重指数≥50公斤/平方米的重度肥胖患者中,支持使用Xa因子抑制剂的数据很少:本研究旨在评估Xa因子抑制剂在治疗体重≥50 kg/m2和/或体重≥150 kg的心房颤动(AF)和/或静脉血栓栓塞(VTE)时是否与华法林一样安全有效:这是一项多中心回顾性队列研究,研究对象是接受 Xa 因子抑制剂或华法林治疗的房颤和/或 VTE 重度肥胖成年患者。主要有效性结局是中风、全身性栓塞或 VTE 的复合几率;主要安全性结局是大出血的几率。次要结局包括中风或全身性栓塞、VTE、大出血、临床相关的非大出血、全因死亡率、抗凝剂量变化和住院总次数。在开始服用研究药物后的 12 个月内对结果进行评估:共纳入了 1,736 名患者。总体组群的平均体重和体重指数分别为 164.4 千克和 54.6 千克/平方米。各组间发生中风、全身性栓塞或 VTE(OR 1.005,95% CI 0.6 - 1.68)或大出血(OR 0.9,95% CI 0.47 - 1.7)的几率没有差异:这些数据表明,对于体重指数≥50 kg/m2和/或体重≥150 kg的患者,阿哌沙班和利伐沙班是华法林治疗房颤和/或VTE的安全有效的替代药物。
{"title":"Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients","authors":"Paul Dobry ,&nbsp;Stephanie B. Edwin ,&nbsp;Brian Haymart ,&nbsp;Geoffrey D. Barnes ,&nbsp;Scott Kaatz ,&nbsp;Mona A. Ali ,&nbsp;Christopher Giuliano","doi":"10.1016/j.jtha.2024.08.009","DOIUrl":"10.1016/j.jtha.2024.08.009","url":null,"abstract":"<div><h3>Background</h3><div>A paucity of data exists to support the use of factor (F)Xa inhibitors in severely obese patients with a weight of ≥150 kg or body mass index (BMI) of ≥50 kg/m<sup>2</sup>.</div></div><div><h3>Objectives</h3><div>The purpose of this study was to evaluate whether FXa inhibitors are as safe and effective as warfarin for the treatment of atrial fibrillation (AF) and/or venous thromboembolism (VTE) in individuals with a BMI of ≥50 kg/m<sup>2</sup> and/or weight of ≥150 kg.</div></div><div><h3>Methods</h3><div>This was a multicenter retrospective cohort study of severely obese adult patients with AF and/or VTE treated with a FXa inhibitor or warfarin. The primary effectiveness outcome was composite odds of stroke, systemic embolism, or VTE; the primary safety outcome was odds of major bleeding. Secondary outcomes included incidence of stroke or systemic embolism, VTE, major bleeding, clinically relevant nonmajor bleeding, all-cause mortality, change in anticoagulation, and total number of hospital encounters. Outcomes were assessed for 12 months following initiation of study drug.</div></div><div><h3>Results</h3><div>A total of 1736 patients were included. The mean weight and BMI of the overall cohort were 164.4 kg and 54.6 kg/m<sup>2</sup>, respectively. There was no difference in odds of stroke, systemic embolism or VTE (odds ratio, 1.005; 95% CI, 0.6-1.68), or major bleeding (odds ratio, 0.9; 95% CI, 0.47-1.7) between groups.</div></div><div><h3>Conclusion</h3><div>These data suggest that apixaban and rivaroxaban are safe and effective alternatives to warfarin for the treatment of AF and/or VTE in individuals with a BMI of ≥50 kg/m<sup>2</sup> and/or weight of ≥150 kg.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Pages 3500-3509"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low von Willebrand factor—unraveling an enigma wrapped in a conundrum 低 VWF--揭开谜团中的谜底。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.jtha.2024.08.015
James S. O’Donnell , Ross I. Baker , Ferdows Atiq
The 2021 ASH ISTH NHF WFH guidelines recommendation that patients with von Willebrand factor (VWF) levels of 30 to 50 IU/dL and an increased bleeding phenotype be categorized as type 1 von Willebrand disease (VWD) rather than Low VWF has proved controversial. However, in support of that decision, recent data have demonstrated that individuals with partial quantitative VWF deficiency exhibit an age-dependent evolving phenotype and confirmed that Low VWF represents a subgroup within heterogeneous type 1 VWD. Nonetheless, type 1 VWD heterogeneity continues to pose significant diagnostic challenges. In this Forum article, we address outstanding issues critical to preventing the inappropriate overdiagnosis of type 1 VWD while maximizing access to healthcare and minimizing diagnostic delays. In addition, we propose an algorithm for type 1 VWD diagnosis. This algorithm pays special attention to individuals with plasma VWF levels in the 30 to 50 IU/dL range who have no or minimal bleeding history and have not yet been exposed to significant hemostatic challenges.
2021 年 ASH ISTH NHF WFH 指南建议将 VWF 水平为 30-50 IU/dL 且出血表型增加的患者归类为 1 型 VWD,而不是低 VWF,这一建议引起了争议。然而,为了支持这一决定,最近的数据表明,部分定量 VWF 缺乏的患者表现出与年龄相关的演变表型,并证实低 VWF 代表了异质性 1 型 VWD 中的一个亚组。尽管如此,1 型 VWD 的异质性仍给诊断带来巨大挑战。在这篇论坛文章中,我们探讨了一些悬而未决的问题,这些问题对于防止不适当地过度诊断 1 型 VWD 至关重要,同时还能最大限度地提高医疗服务的可及性和减少诊断延误。此外,我们还提出了一种 1 型 VWD 诊断算法。该算法特别关注血浆 VWF 水平在 30-50 IU/dL 范围内、无出血史或出血史极少、尚未面临重大止血挑战的个体。
{"title":"Low von Willebrand factor—unraveling an enigma wrapped in a conundrum","authors":"James S. O’Donnell ,&nbsp;Ross I. Baker ,&nbsp;Ferdows Atiq","doi":"10.1016/j.jtha.2024.08.015","DOIUrl":"10.1016/j.jtha.2024.08.015","url":null,"abstract":"<div><div>The 2021 ASH ISTH NHF WFH guidelines recommendation that patients with von Willebrand factor (VWF) levels of 30 to 50 IU/dL and an increased bleeding phenotype be categorized as type 1 von Willebrand disease (VWD) rather than Low VWF has proved controversial. However, in support of that decision, recent data have demonstrated that individuals with partial quantitative VWF deficiency exhibit an age-dependent evolving phenotype and confirmed that Low VWF represents a subgroup within heterogeneous type 1 VWD. Nonetheless, type 1 VWD heterogeneity continues to pose significant diagnostic challenges. In this Forum article, we address outstanding issues critical to preventing the inappropriate overdiagnosis of type 1 VWD while maximizing access to healthcare and minimizing diagnostic delays. In addition, we propose an algorithm for type 1 VWD diagnosis. This algorithm pays special attention to individuals with plasma VWF levels in the 30 to 50 IU/dL range who have no or minimal bleeding history and have not yet been exposed to significant hemostatic challenges.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Pages 3383-3388"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142251215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis 小鼠和人类代谢功能障碍相关性脂肪性肝炎的静脉血栓形成和高凝状态增强
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.jtha.2024.08.023
Nilesh Pandey , Sumit Kumar Anand , Harpreet Kaur , Koral S.E. Richard , Lakshmi Chandaluri , Megan E. Butler , Xiaolu Zhang , Brenna Pearson-Gallion , Sumati Rohilla , Sandeep Das , Tarek Magdy , Palaniappan Sethu , Kelley G. Núñez , A. Wayne Orr , Karen Y. Stokes , Paul T. Thevenot , Ari J. Cohen , Oren Rom , Nirav Dhanesha

Background

Patients with metabolic dysfunction-associated steatohepatitis (MASH) are at an increased risk of developing venous thromboembolic events, including deep vein thrombosis (DVT). To date, the study of DVT in MASH has been hampered by the lack of reliable models that mimic the pathologic aspects of human disease.

Objectives

To evaluate DVT severity and hypercoagulability in murine and human MASH.

Methods

Transcriptional changes in the liver, plasma markers of coagulation, and DVT severity were evaluated in mice fed a standard chow diet or a high-fructose, high-fat, and high-cholesterol MASH diet for 24 weeks. Plasma analyses of coagulation markers and thrombin generation assays were performed in a well-characterized cohort of patients with or without MASH.

Results

Mice fed the MASH diet developed steatohepatitis and fibrosis, mimicking human MASH. Liver RNA sequencing revealed a significant upregulation of pathways related to inflammation and coagulation concomitant with increased levels of plasma coagulation markers including increased prothrombin fragment 1+2, thrombin-antithrombin complex, plasminogen activator inhibitor-1 levels, and endothelin 1. MASH exacerbated DVT severity in mice, as evidenced by increased thrombus weight and higher thrombosis incidence (15/15 vs 11/15 in controls, P = .0317). Higher endothelin 1 release and increased apoptosis were found in endothelial cells stimulated with supernatants of palmitate-stimulated HepG2 cells. Patients with MASH exhibited increased levels of plasma coagulation markers and delayed thrombin generation.

Conclusion

We report enhanced DVT severity and hypercoagulability, both in murine and human MASH. Our model of MASH-DVT can facilitate a better understanding of the fundamental mechanisms leading to increased venous thromboembolic events in patients with MASH.
背景:代谢功能障碍相关性脂肪性肝炎(MASH)患者发生静脉血栓栓塞事件(VTE),包括深静脉血栓形成(DVT)的风险增加。迄今为止,对 MASH 患者深静脉血栓形成的研究一直受阻于缺乏模拟人类疾病病理方面的可靠模型:评估小鼠和人类 MASH 的深静脉血栓严重程度和高凝状态:方法:对以饲料或高果糖、高脂肪和高胆固醇 MASH 食物喂养 24 周的小鼠的肝脏转录变化、血浆凝血标志物和深静脉血栓严重程度进行评估。在一组特征明确的 MASH 患者或非 MASH 患者中进行了血浆凝血标志物分析和凝血酶生成测定:结果:喂食 MASH 食物的小鼠出现了脂肪性肝炎和纤维化,与人类 MASH 相似。肝脏 RNA 测序显示,与炎症和凝血相关的通路显著上调,同时血浆凝血标志物增加,包括凝血酶原片段 1+2、凝血酶-抗凝血酶复合物、纤溶酶原激活物抑制剂-1 水平和内皮素 1 增加。用棕榈酸酯刺激的 HepG2 细胞的上清液刺激内皮细胞时,发现内皮素 1 释放更多,细胞凋亡增加。MASH患者的血浆凝血标志物增加,凝血酶生成延迟:我们报告了小鼠和人类 MASH 的深静脉血栓严重程度和高凝状态。我们的 MASH-DVT 模型有助于更好地了解导致 MASH 患者 VTE 增加的基本机制。
{"title":"Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis","authors":"Nilesh Pandey ,&nbsp;Sumit Kumar Anand ,&nbsp;Harpreet Kaur ,&nbsp;Koral S.E. Richard ,&nbsp;Lakshmi Chandaluri ,&nbsp;Megan E. Butler ,&nbsp;Xiaolu Zhang ,&nbsp;Brenna Pearson-Gallion ,&nbsp;Sumati Rohilla ,&nbsp;Sandeep Das ,&nbsp;Tarek Magdy ,&nbsp;Palaniappan Sethu ,&nbsp;Kelley G. Núñez ,&nbsp;A. Wayne Orr ,&nbsp;Karen Y. Stokes ,&nbsp;Paul T. Thevenot ,&nbsp;Ari J. Cohen ,&nbsp;Oren Rom ,&nbsp;Nirav Dhanesha","doi":"10.1016/j.jtha.2024.08.023","DOIUrl":"10.1016/j.jtha.2024.08.023","url":null,"abstract":"<div><h3>Background</h3><div>Patients with metabolic dysfunction-associated steatohepatitis (MASH) are at an increased risk of developing venous thromboembolic events, including deep vein thrombosis (DVT). To date, the study of DVT in MASH has been hampered by the lack of reliable models that mimic the pathologic aspects of human disease.</div></div><div><h3>Objectives</h3><div>To evaluate DVT severity and hypercoagulability in murine and human MASH.</div></div><div><h3>Methods</h3><div>Transcriptional changes in the liver, plasma markers of coagulation, and DVT severity were evaluated in mice fed a standard chow diet or a high-fructose, high-fat, and high-cholesterol MASH diet for 24 weeks. Plasma analyses of coagulation markers and thrombin generation assays were performed in a well-characterized cohort of patients with or without MASH.</div></div><div><h3>Results</h3><div>Mice fed the MASH diet developed steatohepatitis and fibrosis, mimicking human MASH. Liver RNA sequencing revealed a significant upregulation of pathways related to inflammation and coagulation concomitant with increased levels of plasma coagulation markers including increased prothrombin fragment 1+2, thrombin-antithrombin complex, plasminogen activator inhibitor-1 levels, and endothelin 1. MASH exacerbated DVT severity in mice, as evidenced by increased thrombus weight and higher thrombosis incidence (15/15 vs 11/15 in controls, <em>P</em> = .0317). Higher endothelin 1 release and increased apoptosis were found in endothelial cells stimulated with supernatants of palmitate-stimulated HepG2 cells. Patients with MASH exhibited increased levels of plasma coagulation markers and delayed thrombin generation.</div></div><div><h3>Conclusion</h3><div>We report enhanced DVT severity and hypercoagulability, both in murine and human MASH. Our model of MASH-DVT can facilitate a better understanding of the fundamental mechanisms leading to increased venous thromboembolic events in patients with MASH.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Pages 3572-3580"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Annoucements
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/S1538-7836(24)00683-4
{"title":"Annoucements","authors":"","doi":"10.1016/S1538-7836(24)00683-4","DOIUrl":"10.1016/S1538-7836(24)00683-4","url":null,"abstract":"","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 12","pages":"Page 3652"},"PeriodicalIF":5.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Thrombosis and Haemostasis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1